Nanotein Raises Series A Funding to Bring cGMP Products to Market

Series A Capital Raised

We are excited to announce that Nanotein recently closed a monumental round of capital investment funding! The raise will enable Nanotein to bring the cGMP version of our flagship NanoSpark™ STEM-T Soluble T Cell Activator to market and provide funding for the manufacturing ramp-up of the newly released NanoSpark™ GROW-NK.

We will also be finalizing the development and launch of NanoSpark™ EVEN-T, the latest addition to our NanoSpark™ activator product line for T cell expansion applications with a defined CD4:CD8 ratio.

We’re Investing in Our Team

Nanotein is using this funding opportunity to hire the best and brightest, expanding our team to meet the growing needs of our valued customers. Check back soon for more information.

We are grateful to our dedicated team, customers, and investors who have been instrumental in this endeavor. Our success is because of you. Stay tuned—great things are happening!